ReposiTrak (NYSE:TRAK) Issues Earnings Results

ReposiTrak (NYSE:TRAK) issued its quarterly earnings results on Tuesday. The company reported $0.09 earnings per share (EPS) for the quarter, Zacks reports. ReposiTrak had a return on equity of 14.37% and a net margin of 30.52%.The firm had revenue of $5.86 million for the quarter.

Here are the key takeaways from ReposiTrak’s conference call:

• SaaS conversion: ReposiTrak has converted over $7M of one-time revenue to recurring SaaS, increasing recurring revenue from 62% to >98%, which supports higher contribution margins and more predictable revenue.
• Quarterly financials and balance sheet: Q2 revenue rose 7% to $5.9M, operating income increased 34% to $1.8M, GAAP net income was $1.7M (EPS up 13%), and the company holds ≈$28.7M cash with zero bank debt.
• Product & IP investment: The company is investing in AI-driven “Touchless Traceability,” filed two patents (adding to a 9‑patent U.S. portfolio) and claims AI-based detect-and-correct capabilities that it says create a durable competitive moat.
• Capital returns: ReposiTrak repurchased ~80k shares for $1.1M in the quarter, has $6.7M remaining on its buyback authorization, is redeeming preferred shares on a quarterly schedule, and has raised the dividend three times (aiming to return ~50% of operating cash to shareholders).
• Adoption challenges and risks: High supplier data error rates (estimated 50–70%) make traceability complex and slow onboarding, meaning longer sales cycles; AI hype and food inflation could be short‑term headwinds despite expected demand from the looming FDA deadline.

ReposiTrak Price Performance

NYSE TRAK opened at $10.12 on Wednesday. The stock’s 50 day simple moving average is $11.65 and its 200 day simple moving average is $14.14. ReposiTrak has a one year low of $9.90 and a one year high of $23.72. The firm has a market cap of $185.07 million, a PE ratio of 28.11 and a beta of 0.45.

Insider Buying and Selling at ReposiTrak

In related news, Director Ronald C. Hodge sold 18,906 shares of ReposiTrak stock in a transaction dated Tuesday, December 23rd. The stock was sold at an average price of $13.16, for a total value of $248,802.96. Following the completion of the transaction, the director directly owned 561,869 shares of the company’s stock, valued at $7,394,196.04. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Randall K. Fields sold 7,500 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $13.30, for a total transaction of $99,750.00. Following the transaction, the chief executive officer owned 175,000 shares in the company, valued at approximately $2,327,500. This trade represents a 4.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 112,547 shares of company stock valued at $1,388,173. Corporate insiders own 41.00% of the company’s stock.

Institutional Trading of ReposiTrak

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers lifted its stake in shares of ReposiTrak by 69.1% in the 2nd quarter. Rhumbline Advisers now owns 18,036 shares of the company’s stock valued at $354,000 after purchasing an additional 7,371 shares during the period. American Century Companies Inc. increased its holdings in ReposiTrak by 17.4% in the second quarter. American Century Companies Inc. now owns 23,344 shares of the company’s stock valued at $459,000 after purchasing an additional 3,455 shares during the last quarter. Jane Street Group LLC acquired a new position in ReposiTrak in the second quarter valued at about $802,000. BNP Paribas Financial Markets boosted its holdings in ReposiTrak by 63.5% during the second quarter. BNP Paribas Financial Markets now owns 1,633 shares of the company’s stock worth $32,000 after buying an additional 634 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of ReposiTrak by 397.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,620 shares of the company’s stock worth $71,000 after buying an additional 2,892 shares during the period. Institutional investors own 27.35% of the company’s stock.

Analyst Ratings Changes

TRAK has been the topic of several analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of ReposiTrak in a report on Monday, December 29th. Wall Street Zen lowered shares of ReposiTrak from a “buy” rating to a “hold” rating in a research report on Saturday, January 17th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold”.

About ReposiTrak

ReposiTrak, trading on the New York Stock Exchange under the symbol TRAK, is a provider of cloud-based supply chain compliance and transparency solutions. The company’s platform enables retailers, suppliers and manufacturers to manage, share and validate product data throughout the supply chain. Through its Software-as-a-Service (SaaS) offering, ReposiTrak helps organizations ensure adherence to regulatory requirements, industry standards and retailer-specific guidelines for food safety, sustainability, labeling and quality assurance.

At the core of ReposiTrak’s offerings is its DataHub, a centralized repository that captures critical information such as product specifications, certifications, catch-weight data, temperature logs and recall notifications.